Back to Charles Schwab Investment Management Inc. Charles Schwab Investment Management Inc.

AXSMAXSM

Showing 8 of 29 quarters

Position history for Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc.'s holdings in Axsome Therapeutics, Inc.

Yes. Charles Schwab Investment Management holds 316,104 shares of AXSM (Axsome Therapeutics), worth $77.4M, as of its Q2 2026 13F filing. It reduced the position by 79,014 shares (-20.0%) from Q1 2026. Charles Schwab Investment Management has held AXSM since Q2 2019, across 29 quarterly 13F filings.

Current Value

$77.4M

Current Shares

316,104

Total Value Change

+$48.4M

Total Shares Change

-6,492

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
316,104
-20.0%
$77.4M0.0%$244.77
0
2026-Q1
Decreased
395,118
-1.9%
$66.8M0.0%$169.02
0
2025-Q4
Increased
402,700
+5.4%
$73.5M0.0%$182.64
31
2025-Q3
Increased
382,047
+7.1%
$46.4M0.0%$121.45
31
2025-Q2
Increased
356,651
+5.8%
$37.2M0.0%$104.39
31
2025-Q1
Increased
337,246
+2.8%
$39.3M0.0%$116.63
30
2024-Q4
Increased
328,034
+1.7%
$27.8M0.0%$84.61
29
2024-Q3
Increased
322,596
+4.1%
$29M0.0%$89.87
30

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used